Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-019 CAR-T in R/R B-cell Lymphoma and B-ALL
NCT03854994Phase 1Unknown
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tesevatinib in B-cell lymphoma (BCL) and acute lymphoblastic leukemia (ALL), sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Primary endpoints: Number of Participants with severe cytokine release syndrome at 14 days and Copies numbers of CAR in peripheral blood at 1 year. Status: unknown.
02
Drugs
tesevatinib
03
Conditions
B-cell lymphoma (BCL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03854994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854994.